Innovative Project for the Treatment of Ovarian Cancer

The project titled “In Vitro/In Vivo Potential of Cantradine Encapsulated and Trastuzumab Conjugated Niosomes in HER2 Positive Ovarian Cancer” led by Ege University Institute of Nuclear Sciences faculty member Prof. Dr. Emin İlker Medine was found eligible for support within the scope of TÜBİTAK-ARDEB 1001-Scientific and Technological Research Projects Support Program.

Ege University Rector Prof. Dr. Necdet Budak welcomed and congratulated Prof. Dr. Sabriye Yuşan, Director of the Institute of Nuclear Sciences, and Prof. Dr. Emin İlker Medine, Executive Director of the Project, in his office and said, “Our exemplary science production ecosystem that we have created in our award-winning, pioneering research university with full institutional accreditation and student orientation continues to bear fruit. Our research and development, innovation, project and publication numbers, which we have transformed into a sustainable culture at our university, are reaching a higher level every day. Our scientists are bringing more qualified research and projects to the world of science and literature with the research university label. The project prepared by Prof. Dr. Emin İlker Medine, a faculty member of the Institute of Nuclear Sciences, and his team with an innovative perspective for the treatment of ovarian cancer was found eligible for support by TÜBİTAK. I congratulate our professor and his team and wish them success in their work.”

Ege University Institute of Nuclear Sciences faculty member Prof. Dr. Emin İlker Medine said, “Ovarian cancer is a type of cancer that is more likely to occur in people who have had breast cancer, the most common type of cancer in women. Ovarian cancer treatment usually includes surgery and chemotherapy. The drugs used affect healthy cells as well as cancerous cells. However, the doses needed for treatment do not reach the cancerous cells. To overcome these disadvantages, targeted drug delivery systems designed in the light of nanotechnology are preferred. In this project, Cantradine, a terpene secreted by the Spanish beetle after ovulation to protect the egg from environmental microorganisms, will be used. Cantradine will be encapsulated in niosome nanoparticles and trastuzumab conjugation will be performed to target HER2+ ovarian cancer cells and their in vitro/in vivo potential will be investigated.”